Key result
A revised minimal adenoviral helper plasmid comprising E2A, L4-22K, and VA RNA I genes yielded high titer AAV preps in HEK293 cells, challenging the necessity of E4orf6.
Why the study?
AAV production remains intricate, expensive, and mechanistically underexplored, prompting re-examination and optimization of the adenoviral helper gene requirements to enhance manufacturing efficiencies in mammalian cells.
The identification of E2A, L4-22K, and VA RNA I as the minimal adenoviral helper genes sufficient for AAV production in HEK293 cells provides novel reagents with improved safety and manufacturing efficiency for gene therapy.
May facilitate scalable AAV gene therapy production; extends manufacturing strategies for cardiovascular vector development.
The replication-defective adeno-associated virus (AAV) is extensively utilized as a research tool or vector for gene therapy. The production process of AAV remains intricate, expensive, and mechanistically underexplored. With the aim of enhancing AAV manufacturing efficiencies in mammalian cells, we revisited the questions and optimization surrounding the requirement of the various adenoviral helper genes in enabling AAV production. First, we refined the minimal set of adenoviral genes in HEK293 AAV production to E2A , L4-22 K /33 K , and VA RNA I . These findings challenge the previously accepted necessity of adenoviral E4orf6 in AAV production. In addition, we identified L4-22 K genes as crucial helpers for AAV production. Next, a revised minimal adenoviral helper plasmid comprising E2A , L4-22 K , and VA RNA I genes was designed and demonstrated to yield high titer and potent AAV preps in HEK293 transient transfection. Lastly, stable packaging cells harboring inducible E2A and L4-22 K genes were shown to maintain AAV production yields comparable to transient transfection over a culture period of ∼10 weeks. Combined, these findings further our understanding of adenoviral helper function in mammalian AAV production and provide novel plasmid and cell-line reagents with an improved safety profile for potential broad applicability in the research and gene therapy community.
No takes yet. Share an insight, caveat, or question.
Doshi et al. (2024) studied this question. Minimal adenoviral helper plasmid comprising E2A, L4-22K, and VA RNA I genes was evaluated on AAV production yields. A revised minimal adenoviral helper plasmid comprising E2A, L4-22K, and VA RNA I genes yielded high titer AAV preps in HEK293 cells, challenging the necessity of E4orf6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: